The use of beta blockers for the reduction of mortality after myocardial infarction.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000526:Alprenolol / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D009664:Norway; D010096:Oxprenolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011897:Random Allocation; D013999:Timolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D010096:Oxprenolol; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D011217:Practolol